Oncternal Therapeutics
BiotechnologyView the employees at
Oncternal Therapeutics-
Mary Breitmeyer Vice President Technical Operations & Alliance Management at Oncternal Therapeutics
-
Fallbrook, California, United States
-
Rising Star
Suzanne Munson Executive Assistant | Office Management | Event Planning | Logistics Management | Start Ups-
Yuma, Arizona, United States
-
Rising Star
Brad Webre Vice President at Oncternal Therapeutics-
San Diego, California, United States
-
Rising Star
Steve Hamburger SVP, Regulatory Affairs and Quality at Oncternal Therapeutics-
Fort Myers, Florida, United States
-
Rising Star
Shuguang Bi Sr. Director - CAR T Therapy Development and Manufacturing-
San Diego, California, United States
-
Top 5%
Overview
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
-